Pancreatic Cancer Research

ResearcherShandong UniversityActive in the last 2 years

Yongsheng Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3734-3886; OpenAlex author ID A5101544188. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: none · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper

Papers 9

  1. BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1. Co-author DOI 10.1002/advs.202306298↗
  2. LINC01137 facilitates pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-2411868/v1↗
  3. HOXA10 promote pancreatic cancer progression via directly activating canonical NF-κB signaling pathway. Co-author DOI 10.1093/carcin/bgac042↗
  4. LINC01137 involvement in pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-1516835/v1↗
  5. LINC01137 facilitate pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-2065916/v1↗
  6. DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1155/2019/8656282↗
  7. SFRP4 is a prognostic marker and correlated with Treg cell infiltration in pancreatic ductal adenocarcinoma. Co-author PMID 30906634↗
  8. High expression of WNT7A predicts poor prognosis and promote tumor metastasis in pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41598-018-34094-3↗
  9. The small-molecule IAP antagonist AT406 inhibits pancreatic cancer cells in vitro and in vivo. Co-author DOI 10.1016/j.bbrc.2016.07.011↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lijie Han · 4 shared papers, 2022–2024 · strength 0.56
  2. Yizhi Cao · 4 shared papers, 2022–2024 · strength 0.56
  3. Chenghong Peng · 4 shared papers, 2022–2024 · strength 0.56
  4. Jiaxin Luo · 3 shared papers, 2022–2024 · strength 0.43
  5. Lingxi Jiang · 3 shared papers, 2022–2024 · strength 0.41
  6. Minwei Yang · 4 shared papers, 2018–2022 · strength 0.41
  7. Jiewei Lin · 3 shared papers, 2022–2023 · strength 0.41
  8. Zengyu Feng · 3 shared papers, 2022–2023 · strength 0.41
  9. Kexian Li · 3 shared papers, 2022–2023 · strength 0.41
  10. Kai Qin · 3 shared papers, 2022–2023 · strength 0.41
  11. Yongwei Sun · 3 shared papers, 2019–2022 · strength 0.32
  12. Hao Chen · 2 shared papers, 2023–2024 · strength 0.30
  13. Jiancheng Wang · 2 shared papers, 2022–2023 · strength 0.28
  14. Hao Chen · 2 shared papers, 2022 · strength 0.26
  15. Xueliang Fu · 3 shared papers, 2018–2019 · strength 0.25
  16. Junfeng Zhang · 2 shared papers, 2019–2022 · strength 0.24
  17. Ruizhe He · 2 shared papers, 2018–2019 · strength 0.17
  18. Jian‐Yu Yang · 2 shared papers, 2019 · strength 0.16
  19. Dejun Liu · 2 shared papers, 2019 · strength 0.16
  20. Rong Hua · 2 shared papers, 2019 · strength 0.16
  21. Yan‐Miao Huo · 2 shared papers, 2019 · strength 0.16
  22. Xiaohua Jiang · 1 shared paper, 2022 · strength 0.16
  23. Jiao Li · 1 shared paper, 2022 · strength 0.16
  24. Jiejie Qin · 1 shared paper, 2024 · strength 0.15
  25. Xiaomei Tang · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.